Department of Pathology, Stanford University School of Medicine, Palo Alto, CA, USA.
Histocompatibility, Immunogenetics and Disease Profiling Laboratory, Stanford Blood Center, Palo Alto, CA, USA.
Mult Scler. 2019 May;25(6):772-782. doi: 10.1177/1352458518770019. Epub 2018 Apr 23.
The association between HLA-DRB115:01 with multiple sclerosis (MS) susceptibility is well established, but the contribution of the tightly associated HLA-DRB501:01 allele has not yet been completely ascertained. Similarly, the effects of HLA-DRB1*04:01 alleles and haplotypes, defined at the full-gene resolution level with MS risk remains to be elucidated.
To characterize the molecular architecture of class II HLA-DR15 and HLA-DR4 haplotypes associated with MS.
Next-generation sequencing was used to determine HLA-DQB1, HLA-DQA1, and HLA-DRB1/4/5 alleles in 1403 unrelated European-American patients and 1425 healthy unrelated controls. Effect sizes of HLA alleles and haplotypes on MS risk were measured by odds ratio (OR) with 95% confidence intervals.
HLA-DRB115:01:01:01SG (OR = 3.20, p < 2.2E-16), HLA-DRB501:01:01 (OR = 2.96, p < 2.2E-16), and HLA-DRB501:01:01v1_STR1 (OR = 8.18, p = 4.3E-05) alleles all occurred at significantly higher frequencies in MS patients compared to controls. The most significant predis-posing haplotypes were HLA-DQB106:02:01~ HLA-DQA101:02:01:01SG~HLA-DRB115:01:01:01SGHLA-DRB501:01:01 and HLA-DQB106:02:01HLA-DQA101:02:01:01SG~HLA-DRB115:01:01:01SGHLA-DRB501:01:01v1_STR1 (OR = 3.19, p < 2.2E-16; OR = 9.30, p = 9.7E-05, respectively). Analyses of the HLA-DRB104 cohort in the absence of HLA-DRB115:01 haplotypes revealed that the HLA-DQB103:01:01:01HLA-DQA103:03:01:01~HLA-DRB104:01:01:01SGHLA-DRB401:03:01:01 haplotype was protective (OR = 0.64, p = 0.028), whereas the HLA-DQB103:02:01HLA-DQA103:01:01~HLA-DRB104:01:01:01SG~HLA-DRB4*01:03:01:01 haplotype was associated with MS susceptibility (OR = 1.66, p = 4.9E-03).
HLA-DR15 haplotypes, including genomic variants of HLA-DRB5, and HLA-DR4 haplotypes affect MS risk.
HLA-DRB115:01 与多发性硬化症(MS)易感性之间的关联已得到充分证实,但与 HLA-DRB501:01 紧密相关的等位基因的贡献尚未完全确定。同样,HLA-DRB1*04:01 等位基因和单体型的影响,在全基因分辨率水平上与 MS 风险相关,仍有待阐明。
阐明与 MS 相关的 II 类 HLA-DR15 和 HLA-DR4 单体型的分子结构。
使用下一代测序技术确定 1403 名无关欧洲裔美国患者和 1425 名健康无关对照的 HLA-DQB1、HLA-DQA1 和 HLA-DRB1/4/5 等位基因。HLA 等位基因和单体型对 MS 风险的影响大小通过比值比(OR)及其 95%置信区间来衡量。
与对照组相比,HLA-DRB115:01:01:01SG(OR=3.20,p<2.2E-16)、HLA-DRB501:01:01(OR=2.96,p<2.2E-16)和 HLA-DRB501:01:01v1_STR1(OR=8.18,p=4.3E-05)等位基因在 MS 患者中均以更高的频率发生。最显著的易感单体型是 HLA-DQB106:02:01HLA-DQA1*01:02:01:01SGHLA-DRB115:01:01:01SG~HLA-DRB501:01:01 和 HLA-DQB106:02:01~HLA-DQA101:02:01:01SGHLA-DRB1*15:01:01:01SGHLA-DRB501:01:01v1_STR1(OR=3.19,p<2.2E-16;OR=9.30,p=9.7E-05)。在没有 HLA-DRB115:01 单体型的情况下对 HLA-DRB104 队列进行分析,结果表明 HLA-DQB103:01:01:01HLA-DQA1*03:03:01:01HLA-DRB104:01:01:01SG~HLA-DRB401:03:01:01 单体型具有保护作用(OR=0.64,p=0.028),而 HLA-DQB103:02:01~HLA-DQA103:01:01HLA-DRB1*04:01:01:01SGHLA-DRB4*01:03:01:01 单体型与 MS 易感性相关(OR=1.66,p=4.9E-03)。
HLA-DR15 单体型,包括 HLA-DRB5 的基因组变异,以及 HLA-DR4 单体型影响 MS 风险。